The FDA is failing rare disease patients. I’m one of them.

In this powerful conversation, G [Josie] Van Londen, MD, shares her journey with primary mitochondrial disease and the life-changing impact of the investigational drug elamipretide. She describes the invisible toll of her condition, the relief of a long-awaited diagnosis, and the real-world improvements she’s experienced on treatment. As she urges the FDA to reconsider its recent denial, Josie highlights what’s at stake—not just for herself, but for the entire rare disease community.This link contains more resources (podcasts and news articles) as well as action items (to contact legislators and FDA). And here is a link to the podcast transcript with links to explain the terminology/definitions.  General Links:Disclaimers: https://cancersurvivormd.org/disclaimers/Brad Buchanan: https://linktr.ee/bradthechimeraG [Josie] van Londen: https://linktr.ee/cancersurvivormdCancerBridges: https://cancerbridges.org/